sampleCIRS anti-inflammation
98%+ · 5mg · Lyophilized · MW: 3326.8
Bulk discount
3+ pcs
€57.00
−5%
5+ pcs
€54.00
−10%
10+ pcs
€51.00
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
VIP
Vasoactive Intestinal Peptide | Immune Regulation & Neuroprotection
In short
Studied for how it may help your body relax blood vessels and improve blood flow. Research also explores its potential to support your immune system and promote healthy digestion.
Best sellers
Related resources
Ready-to-use starter kit
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide involved in the natural regulation of the immune and nervous systems. At the molecular level, it binds to VPAC1 and VPAC2 receptors, triggering pathways that suppress pro-inflammatory cytokines and modulate cellular immune responses. Researchers are studying this molecule in vitro and in animal models to understand its mechanisms in chronic inflammatory response syndrome (CIRS), autoimmune conditions, and pulmonary diseases. This product is strictly research-grade and is not an approved medication or therapeutic treatment for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective properties. Acting through VPAC1 and VPAC2 receptors, VIP regulates immune function, vascular tone, circadian rhythms, and neurological health. It has been extensively studied for chronic inflammatory response syndrome (CIRS), pulmonary conditions, autoimmune diseases, and most recently COVID-19 respiratory failure. The injectable form (Aviptadil/Zyesami) received FDA Fast Track designation for COVID-19 ARDS.
VPAC1/VPAC2 dual activation cAMP/PKA signaling in multiple tissues Anti-inflammatory activity (-50-70% TNF-α) Pleiotropic effects in CNS + GI
VIP binds to VPAC1 and VPAC2 receptors coupled to Gαs proteins, activating adenylate cyclase and increasing cAMP/PKA signaling. This leads to anti-inflammatory effects through inhibition of pro-inflammatory cytokines (IL-6, TNF-α), modulation of T helper cell differentiation, and regulation of innate and adaptive immune responses. Intranasal delivery allows direct brain access via olfactory and trigeminal pathways.
VIP nasal spray is the final step in the Shoemaker Protocol for CIRS from mold/biotoxin exposure. Corrects inflammatory markers (TGF-β1, C4a, MMP9) refractory to other therapies.
Research shows VIP downregulates both inflammatory and autoimmune disease components. Studied in rheumatoid arthritis, Crohn's disease, and multiple sclerosis models.
VIP has bronchodilatory and anti-inflammatory effects in airways. Studied for asthma, COPD, and pulmonary sarcoidosis.
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Morning and evening, or spread throughout day
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Morning and evening, or spread throughout day
VIP nasal spray is typically supplied pre-formulated by compounding pharmacies
Store in refrigerator at 2-8°C
Clear nasal passages before administration
Prime spray bottle before first use (2-3 pumps)
Insert nozzle into nostril, aim slightly outward
Spray while gently inhaling
Alternate nostrils between doses
Do not blow nose immediately after spraying
First dose should be administered under medical supervision with lab monitoring
Pre-VIP labs: TGF-β1, Lipase (baseline)
Post-VIP 15 min labs: TGF-β1, Lipase (to assess response and safety)
Stop immediately if abdominal pain develops or lipase elevates above range
Not -approved as nasal spray - compounded off-label
CIRS patients: Complete Shoemaker Protocol steps 1-11 before starting VIP
Ensure MARCoNS eradicated and environment safe before VIP therapy
Monitor blood pressure - VIP can cause vasodilation
Not recommended during pregnancy or breastfeeding
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
IV Aviptadil in Critical COVID-19 Respiratory Failure - Phase 2b/3 RCT (2022)
Humans | 196 patients | IV infusion | 60 days | 2-fold increased survival odds
Multicenter randomized controlled trial across 10 U.S. hospitals. Aviptadil showed 2-fold increased odds of 60-day survival (OR 2.0, p=0.035). Mechanically ventilated patients showed 10-fold increased survival odds. Significant reduction in IL-6 inflammatory marker.
View the studyVIP Corrects Chronic Inflammatory Response Syndrome (CIRS) (2013)
Humans | CIRS patients | Nasal spray 50mcg | Multiple months | Correction of inflammatory markers
Study demonstrating VIP nasal spray corrects CIRS acquired from water-damaged buildings. Showed correction of proteomics, transcriptomics, and gray matter nuclear atrophy refractory to other therapies.
View the studyIUPHAR Review: VIP and PACAP Receptor Pharmacology (2012)
Review | Comprehensive analysis of VPAC1/VPAC2/PAC1 receptors
Definitive pharmacological review of VIP receptors. Details mechanism of action through Gαs/cAMP/PKA pathway, physiological functions in CNS and periphery, and therapeutic potential for neurodegenerative, inflammatory, and autoimmune diseases.
View the studyVIP Prevents Experimental Arthritis - Nature Medicine (2001)
Mice | CIA model | IP injection | 2 weeks | Complete prevention of joint destruction
Landmark study showing VIP completely prevented joint swelling, cartilage destruction, and bone erosion in collagen-induced arthritis. Therapeutic effect associated with downregulation of both inflammatory and autoimmune components.
View the studyIntranasal VIP Pharmacodynamics and Toxicity (2013)
Animal model | 40-200mcg/mL | 1 week | Safe brain delivery confirmed
Demonstrated VIP can be successfully delivered to the brain via intranasal route. Higher dose (200mcg) improved spatial memory deficits in Alzheimer's model. Only minor reversible nasal irritation observed.
View the studyInhaled VIP in Pulmonary Hypertension (2008)
Humans | 20 PH patients | 100mcg inhaled | Acute study | Selective pulmonary vasodilation
Single 100mcg inhaled aviptadil caused significant selective pulmonary vasodilation, improved stroke volume and mixed venous oxygen saturation. 6 patients showed >20% pulmonary vascular resistance reduction.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
